Clinical Trial Update: KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer [NA]

View source ↗

Summary

A clinical trial evaluating KeraStat Skin Therapy for radiation dermatitis in patients with newly diagnosed stage 0-IIIA breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Carcinoma in Situ

Drugs mentioned

• KeraStat Skin Therapy

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Ductal Breast Carcinoma in Situ, Skin Reactions Secondary to Radiation Therapy | NA | Status: WITHDRAWN